J Viral Hepat:乙肝表面抗原定量能否预测E基因型患者的疾病严重程度?

2017-07-17 MedSci MedSci原创

近日,英国国王学院医院(King's College Hospital)的学者在学术期刊《Journal of Viral Hepatitis》上发表了一篇题为“Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?”的论文,探

近日,英国国王学院医院(King's College Hospital)的学者在学术期刊《Journal of Viral Hepatitis》上发表了一篇题为“Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?”的论文,探讨乙肝表面抗原定量水平是否能预测E基因型患者肝病的严重程度。

目前尚未完全证实乙肝表面抗原定量(qHBsAg) 水平是慢性乙型肝炎(CHB)相关肝损伤的标志,但是随着研究的深入,两者的关系越来越紧密了。乙肝表面抗原定量与e抗原阴性的BC基因型的肝病进展相关,但尚不清楚所有基因型是否与上述结果一致。在这个单中心、横断面观察研究中,我们评估了qHBsAg水平是否能预测E基因型患者肝病的严重程度。

方法:入组患者HBV DNA>2000 IU/mL 伴或不伴有ALT的异常。在对患者进行肝组织活检的同时评估了患者的人口学特征、病毒标记物、生化指标和qHBsAg水平。根据纤维化严重程度将患者分为三组:轻度(F0-1),中度(F2-4)、重度(F5-6),根据炎症坏死分级分为轻中度(NI 0 - 3)和重度炎症(NI≥4)

结果:共纳入259e抗原阴性的E基因型的初治慢乙肝患者。患者平均年龄为38岁,61%为男性。进展期(重度)纤维化患者ALTHBV DNA水平更高,qHBsAg水平更低,qHBsAg / DNA的比值更小。NI≥4的患者ALTHBV DNA水平更高,qHBsAg / DNA的比值更小。qHBsAgHBV DNA水平之间无相关性。

结论:肝脏纤维化越重,HBsAg水平较低。qHBsAgHBV DNA水平之间没有相关性。这可能反映了在HBeAg阴性的E基因型的进展期肝病患者中,HBV病毒的复制与转录活性或HBsAg特异性表达之间是不一致的。

原始出处:

Chakrabarty G, Bruce M, Horner M, et al. Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients? J Viral Hepat. 2017 Jul 14. doi: 10.1111/jvh.12756.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890828, encodeId=5aa418908285a, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Oct 30 07:51:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785942, encodeId=3d101e85942e2, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 31 03:51:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426778, encodeId=89ae1426e78c5, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623247, encodeId=3864162324e63, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223444, encodeId=2fb02234449a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jul 18 07:51:05 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890828, encodeId=5aa418908285a, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Oct 30 07:51:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785942, encodeId=3d101e85942e2, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 31 03:51:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426778, encodeId=89ae1426e78c5, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623247, encodeId=3864162324e63, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223444, encodeId=2fb02234449a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jul 18 07:51:05 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890828, encodeId=5aa418908285a, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Oct 30 07:51:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785942, encodeId=3d101e85942e2, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 31 03:51:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426778, encodeId=89ae1426e78c5, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623247, encodeId=3864162324e63, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223444, encodeId=2fb02234449a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jul 18 07:51:05 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 gwc384
  4. [GetPortalCommentsPageByObjectIdResponse(id=1890828, encodeId=5aa418908285a, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Oct 30 07:51:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785942, encodeId=3d101e85942e2, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 31 03:51:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426778, encodeId=89ae1426e78c5, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623247, encodeId=3864162324e63, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223444, encodeId=2fb02234449a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jul 18 07:51:05 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1890828, encodeId=5aa418908285a, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Oct 30 07:51:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785942, encodeId=3d101e85942e2, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 31 03:51:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426778, encodeId=89ae1426e78c5, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623247, encodeId=3864162324e63, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Jul 18 15:51:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223444, encodeId=2fb02234449a, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jul 18 07:51:05 CST 2017, time=2017-07-18, status=1, ipAttribution=)]
    2017-07-18 1dd8c52fm63(暂无匿称)

    继续关注

    0

相关资讯

重磅:厦门大学附属中山医院关于粪菌移植治疗慢性乙型肝炎的研究在线发表于国际肝病领域第一期刊Hepatology!

重磅:厦门大学附属中山医院关于粪菌移植治疗慢性乙型肝炎的研究在线发表于国际肝病领域顶级期刊Hepatology!

四种方法诊断慢乙肝合并轻度肝脂肪变患者肝纤维化比较

作者:张舰琼 天津医科大学研究生院徐亮 李萍 刘勇钢 石瑞芳 宓余强 天津市第二人民医院天津市肝病研究所慢乙肝(慢乙肝)患者合并肝脂肪变很常见。肝脂肪变性对慢乙肝患者肝内炎症及纤维化的影响尚无一致的结论。FibroScan是近年来较常用的无创诊断慢乙肝患者肝纤维化的方法。血清学诊断模型(APRI指数、FIB-4指数、Forns 指数)亦能简便评价慢乙肝患者肝纤维化。本研究回顾性评价了这4 种方法诊

Aliment Pharmacol Ther:抗病毒治疗慢性乙型肝炎,可降低肝癌风险

背景:既往对肝硬化患者的研究表明,进行抗病毒治疗慢性乙型肝炎(CHB),可以降低肝细胞癌(HCC)风险。 目的:本项研究的目标人群定位在伴和不伴肝硬化的CHB患者,探究抗病毒治疗对HCC风险的影响。 方法:研究纳入了2255例CHB患者(来自US队列,973例接受抗病毒治疗)和3653例未接受抗病毒治疗的患者(来自台湾REVEAL-HBV研究)。校正既往已经得到验证的REACH-B风险

《WHO慢性乙型肝炎预防、关怀和治疗指南》中文版发布

2015年5月15日上午,中文版《WHO慢性乙型肝炎预防、关怀和治疗指南》(以下简称为WHO乙肝指南)正式发布。本指南为首个针对慢性乙肝患者进行预防、关怀和治疗的世卫组织指南。指南概览指南建议是按照慢性乙肝患者连续一体关怀体系的结构编写,从初始对疾病分期和治疗指征的评估,开始一线抗病毒治疗,对疾病进展、药物毒性及肝细胞癌发生的监测,到治疗失败时改用二线药物。建议涵盖各年龄段及各种族成人患者。指

J Hepatol:慢性乙型肝炎出现肝脏疾病进展和死亡的危险因素研究

与慢性乙型肝炎(CHB)相关的肝脏疾病进展和死亡率的风险因素知之甚少。 研究纳入CHB出院女患者,多因素Cox比例风险模型,评估肝脏和非肝脏相关危险因素,与肝脏疾病进展(终末期肝病或肝癌)和死亡率的关系。 总体而言,肝脏疾病的进展、肝移植和死亡记录分别有7479 (15.5%)、433 (8.2%)和5299 (11.0%)例。5426 (72.6%)例肝脏疾病进展患者有肝脏相关的危险

ILC 2016:NVR 3-778可安全地降低慢性乙型肝炎患者的HBV DNA的水平

据国际肝脏会议上一项新的报道显示,乙型肝炎病毒核心的抑制剂——NVR 3-778,可安全地减少慢性乙型肝炎病毒感染患者的HBV DNA的水平。